1-4 of 4
Marcy K. Vallone
Close
Sort by
Journal Articles

Multicenter Phase I Studies To Evaluate the Safety, Tolerability, and Clinical Response to Intensive Dosing with the Proteasome Inhibitor PR-171 in Patients with Relapsed or Refractory Hematological Malignancies.

Owen A. O’Connor, PhD, MD, Robert Z. Orlowski, MD, PhD, Melissa Alsina, MD, Keith Stewart, MBChB, Suzanne Trudel, MD, Marcy K. Vallone, Tina M. Woo, Pedro R. Urquilla, MD, Christopher J. Molineaux, PhD, Andre Goy, MD
Journal: Blood
Blood (2006) 108 (11): 2430.
https://doi.org/10.1182/blood.V108.11.2430.2430
Published: 2006
Journal Articles

A Proteasome Specific Binding Assay for Quantitation of Constitutive and Immunoproteasome Active Sites.

Mark K. Bennett, PhD, Monette A. Aujay, BS, Tonia J. Buchholz, MS, Susan D. Demo, PhD, Guy J. Laidig, PhD, Congcong M. Sun, MS, Marcy K. Vallone, BS, Tina Woo, BS, Mark S. Smyth, PhD
Journal: Blood
Blood (2005) 106 (11): 2472.
https://doi.org/10.1182/blood.V106.11.2472.2472
Published: 2005
Journal Articles

Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome.

Christopher J. Kirk, PhD, Mark K. Bennett, PhD, Tonia J. Buchholz, MS, Susan D. Demo, PhD, Mark N. Ho, BS, Jing Jiang, BS, Guy J. Laidig, PhD, Evan R. Lewis, PhD, Kevin D. Shenk, BS, Mark S. Smyth, PhD, Congcong M. Sun, MS, Marcy K. Vallone, BS, Tina M. Woo, BS, Christopher J. Molineaux, PhD
Journal: Blood
Blood (2005) 106 (11): 609.
https://doi.org/10.1182/blood.V106.11.609.609
Published: 2005
Journal Articles

Biochemical and Cellular Characterization of the Novel Proteasome Inhibitor PR-171.

Susan D. Demo, PhD, Tonia J. Buchholz, MS, Guy J. Laidig, PhD, Francesco Parlati, PhD, Kevin D. Shenk, BS, Mark S. Smyth, PhD, Carol M. Sullivan, BA, Congcong M. Sun, MS, Marcy K. Vallone, BS, Tina Woo, BS, Mark K. Bennett, PhD
Journal: Blood
Blood (2005) 106 (11): 1588.
https://doi.org/10.1182/blood.V106.11.1588.1588
Published: 2005